Study reports senescence-independent SASP drives inflammatory cascade and therapy resistance in HNSCC

A study published in Functional & Integrative Genomics reports that a senescence-independent secretory phenotype driven by dsRNA and autophagy promotes therapeutic resistance in head and neck cancer, suggesting autophagy inhibition as a potential strategy to disrupt this inflammatory loop.

Researchers from Qilu Hospital of Shandong University evaluated the regulatory mechanisms of the senescence-associated secretory phenotype (SASP) driven by double-stranded RNA (dsRNA)-mediated innate immune activation after chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC).

Using the dsRNA mimic poly(I:C) on CAL27 cells alongside chloroquine intervention to inhibit autophagy, the investigators determined that dsRNA-mediated immune stimulation triggers an NF-κB-dependent, senescence-independent SASP.

This secretory phenotype occurs in an autophagy-dependent manner without inducing classic cellular senescence markers or proliferative arrest.

The study identified CXCL1 as a key mediator of this SASP subtype, which initiates an IL-6-mediated transcellular cascade that activates SASP in tumor-associated macrophages and remodels the tumor microenvironment.

Inhibition of autophagy using chloroquine successfully suppressed this SASP, reduced IL-6 secretion, and disrupted the tumor-macrophage inflammatory loop.

The findings demonstrate that the pathogenic inflammatory secretome (SASP) can be decoupled from the proliferative arrest characteristic of classic cellular senescence.

By establishing that highly proliferative cells can exhibit a senescence-independent SASP, the research highlights a parallel pathway of inflammatory tissue damage and therapy resistance that bypasses standard senescent cell markers.

The critical role of autophagy in driving this senescence-independent SASP reveals a specific molecular target to disrupt the downstream inflammatory cascade in HNSCC.

For the longevity and biotechnology sectors, the decoupling of SASP from cell-cycle arrest indicates that therapies aimed strictly at clearing classic senescent cells may leave active, non-senescent cellular sources of SASP unaffected.

The findings highlight the therapeutic relevance of autophagy modulation, but present a complex paradigm: while some longevity approaches focus on autophagy restoration, this oncology context requires autophagy inhibition to block the inflammatory cascade.

Preclinical and clinical evaluation of the validated TLR3-autophagy-NF-κB-IL-6 signature as a prognostic biomarker for oral squamous cell carcinoma.

Further research into combining autophagy inhibitors with standard chemoradiotherapy and immunotherapy regimens to overcome resistance in HNSCC.